How confidence intervals become confusion intervals

BMC Medical Research Methodology

Volumn 13, Issue 1, 2013, Pages

  McCormack, James ^a   Vandermeer, Ben ^b   Allan, G Michael ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Confidence intervals; Evidence based medicine; Statistical analysis; Statistical significance

Indexed keywords

ANTICOAGULANT AGENT; BENZAZEPINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; QUINOXALINE DERIVATIVE; VARENICLINE;

ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; EVIDENCE BASED MEDICINE; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNCERTAINTY;

ANTICOAGULANTS; BENZAZEPINES; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME; UNCERTAINTY;

EID: 84886732032     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-13-134     Document Type: Review

References (20)

1. On the origins of the.05 level of statistical significance. Cowles M, Davis C, Am Psychol 1982 37 553 558
2. Effect of different antilipidemic agents and diets on mortality: A Systematic Review. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC, Arch Intern Med 2005 165 725 730 10.1001/archinte.165.7.725 15824290
3. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK, Arch Intern Med 2006 166 2307 2313 10.1001/archinte.166.21.2307 17130382
4. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D, J Am Coll Cardiol 2008 52 1769 1781 10.1016/j.jacc.2008.08.039 19022156
5. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, et al. BMJ 2009 338 2376 10.1136/bmj.b2376 19567909
6. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, et al. Arch Intern Med 2010 170 1024 1031 10.1001/archinternmed.2010.182 20585067
7. Dabigatran versus warfarin in patients with atrial fibrillation. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. N Engl J Med 2009 361 1139 1151 10.1056/NEJMoa0905561 19717844
8. Apixaban versus warfarin in patients with atrial fibrillation. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. N Engl J Med 2011 365 981 992 10.1056/NEJMoa1107039 21870978
9. Hughes S, ARISTOTLE: A major win for apixaban in AF Heartwire 2011 http://www.medscape.com/viewarticle/748682 (accessed November 5, 2013)
10. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Singh S, Loke YK, Spangler JG, Furberg CD, CMAJ 2011 183 1359 1366 10.1503/cmaj.110218 21727225
11. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. Prochaska JJ, Hilton JF, BMJ 2012 344 2856 10.1136/bmj.e2856 22563098
12. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK, Arch Intern Med 2012 172 209 216 10.1001/archinternmed.2011.628 22231610
13. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J, Am J Med 2011 124 621 629 10.1016/j.amjmed.2011.01.018 21592450
14. Sifting the evidence-what's wrong with significance tests? Sterne JA, Davey Smith G, BMJ 2001 322 226 231 10.1136/bmj.322.7280.226 11159626
15. A show of confidence. Rothman KJ, N Engl J Med 1978 299 1362 1363 10.1056/NEJM197812142992410 362205
16. Confidence intervals rather than P values: estimation rather than hypothesis testing. Gardner MJ, Altman DG, Br Med J (Clin Res Ed) 1986 292 746 750 10.1136/bmj.292.6522.746 3082422
17. Beyond the confidence interval. Poole C, Am J Public Health 1987 77 195 199 10.2105/AJPH.77.2.195 3799860
18. Confidence intervals. Bulpitt CJ, Lancet 1987 329 8531 494 497 10.1016/S0140-6736(87)92100-3
19. Reporting research results: recommendations for improving communication. Cooper RJ, Wears RL, Schriger DL, Ann Emerg Med 2003 41 561 564 10.1067/mem.2003.135 12658257
20. P values vs estimates of association with confidence intervals. Cummings P, Koepsell TD, Arch Pediatr Adolesc Med 2010 164 193 196 10.1001/ archpediatrics.2009.266 20124150